The FrontMIND study, a phase III randomized trial, is evaluating tafasitamab in combination with lenalidomide and rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP), as compared to R-CHOP alone, in untreated high-intermediate-risk and high-risk patients with DLBCL (NCT04824092). This evidence concerns the gene DDIT3 and diffuse large B-cell lymphoma.